Description: SC66 is a novel, potent and allosteric inhibitor of AKT with potential anticancer activity, it reduces cell viability in a dose- and time-dependent manner, inhibits colony formation and induces apoptosis in hepatocellular carcinoma (HCC) cells. SC66 exhibits a dual-inhibitory function toward AKT activity with IC50 values of 0.77, 2.85 and 0.47 μg/ml in HepG2, Huh7 and Hep3B cells, respectively. SC66 reduces cell viability in a dose- and time-dependent manner, it also inhibits colony formation and induces apoptosis in hepatocellular carcinoma (HCC) cells.  SC66 treatment led to a reduction in total and phospho-AKT levels. SC66 induced the production of reactive oxygen species (ROS) and DNA damage. SC66 significantly potentiated the effects of both conventional chemotherapeutic and targeted agents, doxorubicin and everolimus, respectively. In vivo, SC66 inhibited tumor growth of Hep3B cells in xenograft models, with a similar mechanism observed in the in vitro model. SC66 had antitumor effects on HCC cells.

 

References: Oncotarget. 2015 Jan 30;6(3):1707-22.

Attribute
[Chem Name]	SC66
[Synonym]	(2E,6E)-2,6-bis(pyridin-4-ylmethylene)cyclohexanone
[CAS No.]	871361-88-5
[Formula]	C18H16N2O
[Molecular]	276.33
[Storage]	-20℃ for 3 years in powder form
[MDL No.]	MFCD05025493
[Form]	Powder

Goods Tag